Birchview Capital, LP Phathom Pharmaceuticals, Inc. Transaction History
Birchview Capital, LP
- $124 Million
- Q3 2025
A detailed history of Birchview Capital, LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 85,000 shares of PHAT stock, worth $1.25 Million. This represents 0.78% of its overall portfolio holdings.
Number of Shares
85,000
Previous 25,000
240.0%
Holding current value
$1.25 Million
Previous $239,000
306.69%
% of portfolio
0.78%
Previous 0.25%
Shares
2 transactions
Others Institutions Holding PHAT
# of Institutions
149Shares Held
65.3MCall Options Held
1.15MPut Options Held
170K-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$183 Million6.03% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$110 Million12.93% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.08MShares$74.6 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.86MShares$56.8 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$51.4 Million50.16% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $575M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...